Human IgG1κ anti-CD38 monoclonal antibody (brand name Darzalex) given intravenously; binds CD38 on leukemic cells to induce ADCC, CDC, ADCP, and apoptosis, and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression.
Human IgG1-kappa anti-CD38 monoclonal antibody that binds CD38 on tumor cells to induce antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis; also depletes CD38+ immunosuppressive cells and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression.
Daratumumab binds CD38 on target cells and triggers Fc-mediated ADCC, complement-dependent cytotoxicity, and antibody-dependent phagocytosis; crosslinking can also induce apoptosis of CD38+ cells.
Fc-enhanced anti-CD19 humanized IgG monoclonal antibody (Monjuvi) that induces ADCC/ADCP and apoptosis of B cells.
Fc-enhanced humanized anti-CD19 IgG monoclonal antibody that binds CD19 on B cells and promotes Fcγ receptor–mediated ADCC and ADCP, leading to apoptosis and depletion of malignant B cells.
Binds CD19 on B cells and recruits FcγR-bearing effector cells to induce ADCC and ADCP, leading to apoptosis and depletion of CD19+ cells.
Actinium-225–conjugated FPI-2053 targeted alpha therapy that binds EGFR/cMET and delivers high-LET alpha radiation causing DNA double-strand breaks and tumor cell kill.
Bispecific anti-EGFR/c-MET humanized antibody (FPI-2053) chelated to DOTA and radiolabeled with actinium-225; targets EGFR/c-MET on tumor cells and delivers high-LET alpha radiation that causes DNA double-strand breaks and tumor cell death, with potential secondary anti-tumor immune activation from antigen release.
The bispecific antibody binds EGFR on tumor cells and delivers actinium‑225 alpha radiation, causing high‑LET DNA double‑strand breaks and lethal damage (apoptosis/necrosis) without requiring immune-cell engagement.
A fully human IgG1 anti-CD20 monoclonal antibody (brand name Kesimpta) that binds a distinct epitope on CD20 on mature B cells, inducing rapid and sustained B-cell depletion primarily via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, with possible direct apoptosis; spares hematopoietic stem cells and plasma cells.
Fully human IgG1 anti‑CD20 monoclonal antibody that binds a distinct epitope on mature B cells and depletes them primarily via complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity (ADCC), with possible direct apoptosis; spares hematopoietic stem cells and plasma cells.
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC; it may also trigger direct apoptosis of the targeted cells.
Subcutaneous T-cell–redirecting bispecific antibody (CD3xCD20) that binds CD3 on T cells and CD20 on B cells to bring them into proximity, activating T-cell cytotoxicity to lyse lymphoma cells.
Bispecific antibody that binds CD3 on T cells and CD20 on B cells, bringing them into proximity to activate and redirect T-cell cytotoxicity to lyse CD20+ B-cell lymphoma cells.
Epcoritamab bridges CD3 on T cells and CD20 on target cells, activating T cells to form an immune synapse and kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.